芳香运脾法及其代表方药对腹泻型肠易激综合征大鼠作用机理的研究
|
摘要
目的
肠易激综合征(Irritable bowel syndrome, IBS)是一种以腹部不适或腹痛、排便习惯和大便性状异常为主要症状而又缺乏胃肠道结构或生化异常的胃肠功能性疾病。研究发现造成IBS的因素是多方面的,以感觉异常和动力改变为特征的内脏高敏感性是其主要发病机制之一。目前认为神经-免疫-内分泌网络失调是对IBS较为全面的认识,胃肠激素、免疫因子作为该网络的中间递质在IBS发病机制中发挥着重要作用。IBS发病广泛,西医治疗以对症处理为主,而无有效的根治措施,中医中药治疗取得了满意的临床疗效,具有广阔的应用前景。
腹泻型肠易激综合征(D-IBS)归属于中医“泄泻”、“腹痛”等范畴,多种致病因素均能影响脾胃升清降浊功能,导致小肠泌清别浊失调,水谷并走肠间,引发泄泻。’芳香运脾类方药,具有补中寓消,消中有补,补不碍滞,消不伤正之功。既能消除阻碍脾胃正常纳运的各种致病因子,以及因脾胃纳运失常而产生的各种病理产物如湿、食、滞等；又能促进脾胃机能的恢复,使之达到健运的正常状态。其代表方药藿香正气具有疏畅中焦气机,宣化湿浊,运脾醒胃之功效,对湿邪停滞,脾胃不和所致外感及内伤腹泻具有明确的临床止泻作用,其双向调整胃肠动力,保护肠屏障,调畅心神的功能,提示本类方药可能成为治疗D-IBS的理想药物。本研究以腹泻型肠易激综合征(D-IBS)为重点,通过观察藿香正气方药对D-IBS大鼠胃肠激素和免疫炎症因子的调节作用,试图阐释芳香运脾方药对于D-IBS内脏敏感性和免疫炎症失衡的调整作用以及相关的药理机制,并为临床应用该类药物治疗D-IBS提供科学翔实的实验依据。
方法
1.以番泻叶灌胃联合肢体束缚应激法复制腹泻型肠易激综合征大鼠模型。
2.通过观察不同浓度藿香正气对模型大鼠大体指标、甩尾时间、直结肠球囊扩张耐受阈值的影响,初步探讨藿香正气对D-IBS大鼠模型敏感性的影响,并确定最佳使用浓度。
3.通过对结肠粘膜匀浆SP、VIP、CGRP、血浆ET含量的测定,探讨藿香正气对相关敏感性胃肠激素的影响。
4.通过测定血浆ET、结肠粘膜匀浆SP、VIP的水平,探讨藿香正气主药藿香水提液、挥发油、以及水油混合成分,对相关胃肠激素的影响。
5.通过脏体指数、血清及结肠粘膜中IL-1β、IL-2浓度、血清CORT的测定,探讨藿香正气对炎症免疫失衡的调节作用。
结果
1.成功改良并复制D-IBS动物模型。模型组大鼠均腹泻,体重呈负增长(P<0.01),免疫器官萎缩(P<0.01)。光镜下结肠组织病理学表现为局部上皮细胞排列不整,杯状细胞增多,粘膜下偶有水肿,间质少许炎性细胞浸润。
2.芳香运脾代表方-藿香正气高、中剂量组不但可以明显抑制模型大鼠体重下降(P<0.01),减少稀便(P<0.05),而且能够明显改善其躯体及肠道敏感性的异常状态(P<0.05),尤以中浓度组(53.6mg/ml)作用最为显著。
3.芳香运脾代表方-藿香正气可显著降低外周SP、VIP、ET水平(P<0.01,P<0.05,P<0.01),维持CGRP含量(P>0.05)。
4.芳香运脾代表药-藿香可显著降低外周SP、VIP及ET含量(P<0.01),藿香水提液、挥发油作用靶点不同。
5.芳香运脾代表方-藿香正气可提高脏体指数(P<0.05),有效降低IL-1B水平(P<0.05),明显提高IL-2含量(P<0.01),发挥免疫调节作用,但对于CORT含量无明显降低作用(P>0.05),。
结论
本研究以番泻叶水煎剂灌胃联合肢体束缚应激法,成功改良并复制了腹泻型肠易激综合征大鼠模型。芳香运脾法代表方-藿香正气通过调节外周胃肠激素水平,促炎因子和抑炎因子平衡,降低内脏敏感性和改善免疫炎性不平衡状态,从而缓解D-IBS症状,发挥其对于D-IBS的治疗作用。芳香运脾法代表药-藿香是通过多成分、多环节、多靶点的综合作用发挥治疗D-IBS的药效,因此在藿香正气制剂过程中不该随意丢弃主药藿香的有效成分。芳香运脾法则及其代表方药调节应激引发神经-内分泌-免疫网络紊乱,是中医学芳香运脾法调畅中焦脾胃气机、恢复脾胃健运功效的科学内涵之一。该法临床治疗D-IBS切入点与从肝论治---痛泻要方不同,该法则以脾胃升降功能失调为主要病机,适用于以腹泻为主证而伴有腹部不适者。
Objective:
Irritable bowel syndrome (IBS) is a common disease with gastrointestinal disorder functions, the clinical syndromes include abdominal pain, diarrhea or constipation, and abnormal bowel evacuation habit. It is without changes of structure and biochemistry. The incidence of IBS is very high, but its pathological mechanism is not completely illuminated. At present, the visceral hypersensitivity characterized by changed dynamic and abnormal sense is one of the important pathogenesis. The disharmony of neuroendocrine-immunity network secretion is advanced cognition.The gastrointestinal peptides and cytokines play important roles in the mechanism as middle transmitters. The common treatment is limited to symptomatic, there is no method to root it out now, while Chinese medicine have satisfying curative effect. So there are broad foregrounds of application of traditional Chinese medicine.
D-IBS belongs to the category of "diarrhea"、"abdominal pain" in traditional Chinese medicine. Its main mechanism is dysfunction of spleen and stomach, which leads to intestinal secretion of other features missing, liquid water can not infiltrate into the bladder,instead into colon, induce diarrea. Fragrant drugs can regulate the function of spleen and stomach, which has the features of elimination and benefit. Huoxiangzhegnqi is representative of fragrant drugs, which can regulate the activities of qi, eliminate the wetness-evil, invigorate the spleen and the stomach. It has good clinical effect on stopping diarrhea. But there is rare reports of research based on D-IBS. The purpose of our study is to explore the cure effect of Huoxiangzhengqi on D-IBS. By D-IBS rats model, we observe the opsonification of HXZQ on gut hormone and cytokine, in order to elucidate the adjusting visceral hypersensitivity and immunological function. We observe the effect of different ingredients in Agastache rugosa on some gut hormones, to discuss the diverse targets on D-IBS. All of our study will provide the scientific and reliable evidence for clinical application.
Methods:
1. D-IBS rats model is established by the combination of tied and intragastric administration Folium Cassiae.
2. Groups with different concentrations of HXZQ were established. Through testing the changes of the general status such as the body weight, the diarrhea condition, tail flick assay, saccule extension in rectum and colon, we try to explain the effect of HXZQ in adjusting the visceral hypersensitivity preliminarily and determine the best dose.
3. The level of SP、VIP、CGRP、ET and CORT were detected by radioimmunoassay and ELISA to show the adjusting effect of HXZQ on gut hormones.
4. In order to explore the effect of different ingredients in Agastache rugosa, we detected the level of SP、VIP and ET.
5. To discuss the adjusting effect of HXZQ on immunological function, we observed the atrophy degree of the spleen and thoracic gland, detected IL-1βand IL-2.
Results:
1. D-IBS rats showed obvious diarrhea, weight loss and immunological organs atrophied. There was no obvious injury by light microscope.
2. HXZQ may obviously degrade the diarrhea rate (P<0.05), inhibit the weight loss (P<0.01),and improve the abnormal visceral hypersensitivity(P<0.05).The medium dose was the best.
3. The medium dose of HXZQ can contribute to adjust the gut hormones, cut down the level of SP、VIP、ET, and keep the expression of CGRP(P>0.05).
4. Agastache rugosa also can adjust gut hormones(P<0.05). And different indigents have different effect targets.
5. The medium dose of HXZQ can improve the lower immunological conditions, degrade the expression of IL-1β(P<0.05) and elevate the level of IL-2 (P<0.01),except CORT(P>0.05).
Conclusions:
The model rats can induce the abnormal visceral hypersensitivity and immunological functions under stress. HXZQ, the representative of fragrant drugs, can adjust the expression of gut hormones and cytokines, improve the neuroendocrine-immunity network secretion to educe the therapeutical effect on D-IBS. Different indigents in Agastache rugosa have different effect targets, so in the procedure of making durgs we should not discard any indigent. Yunpi aromatic herbs and their representatives regulating stress-induced nerve-endocrine-immune network disorder, is one of the scientific content of regulating Qi in stomach and spleen, resuming their normal functions. Clinical treatment is different from the Liver pain Diarrhea, diarrhea accompanied by abdominal discomfort were its main syndromes.
肠易激综合征(Irritable bowel syndrome, IBS)是一种以腹部不适或腹痛、排便习惯和大便性状异常为主要症状而又缺乏胃肠道结构或生化异常的胃肠功能性疾病。研究发现造成IBS的因素是多方面的,以感觉异常和动力改变为特征的内脏高敏感性是其主要发病机制之一。目前认为神经-免疫-内分泌网络失调是对IBS较为全面的认识,胃肠激素、免疫因子作为该网络的中间递质在IBS发病机制中发挥着重要作用。IBS发病广泛,西医治疗以对症处理为主,而无有效的根治措施,中医中药治疗取得了满意的临床疗效,具有广阔的应用前景。
腹泻型肠易激综合征(D-IBS)归属于中医“泄泻”、“腹痛”等范畴,多种致病因素均能影响脾胃升清降浊功能,导致小肠泌清别浊失调,水谷并走肠间,引发泄泻。’芳香运脾类方药,具有补中寓消,消中有补,补不碍滞,消不伤正之功。既能消除阻碍脾胃正常纳运的各种致病因子,以及因脾胃纳运失常而产生的各种病理产物如湿、食、滞等；又能促进脾胃机能的恢复,使之达到健运的正常状态。其代表方药藿香正气具有疏畅中焦气机,宣化湿浊,运脾醒胃之功效,对湿邪停滞,脾胃不和所致外感及内伤腹泻具有明确的临床止泻作用,其双向调整胃肠动力,保护肠屏障,调畅心神的功能,提示本类方药可能成为治疗D-IBS的理想药物。本研究以腹泻型肠易激综合征(D-IBS)为重点,通过观察藿香正气方药对D-IBS大鼠胃肠激素和免疫炎症因子的调节作用,试图阐释芳香运脾方药对于D-IBS内脏敏感性和免疫炎症失衡的调整作用以及相关的药理机制,并为临床应用该类药物治疗D-IBS提供科学翔实的实验依据。
方法
1.以番泻叶灌胃联合肢体束缚应激法复制腹泻型肠易激综合征大鼠模型。
2.通过观察不同浓度藿香正气对模型大鼠大体指标、甩尾时间、直结肠球囊扩张耐受阈值的影响,初步探讨藿香正气对D-IBS大鼠模型敏感性的影响,并确定最佳使用浓度。
3.通过对结肠粘膜匀浆SP、VIP、CGRP、血浆ET含量的测定,探讨藿香正气对相关敏感性胃肠激素的影响。
4.通过测定血浆ET、结肠粘膜匀浆SP、VIP的水平,探讨藿香正气主药藿香水提液、挥发油、以及水油混合成分,对相关胃肠激素的影响。
5.通过脏体指数、血清及结肠粘膜中IL-1β、IL-2浓度、血清CORT的测定,探讨藿香正气对炎症免疫失衡的调节作用。
结果
1.成功改良并复制D-IBS动物模型。模型组大鼠均腹泻,体重呈负增长(P<0.01),免疫器官萎缩(P<0.01)。光镜下结肠组织病理学表现为局部上皮细胞排列不整,杯状细胞增多,粘膜下偶有水肿,间质少许炎性细胞浸润。
2.芳香运脾代表方-藿香正气高、中剂量组不但可以明显抑制模型大鼠体重下降(P<0.01),减少稀便(P<0.05),而且能够明显改善其躯体及肠道敏感性的异常状态(P<0.05),尤以中浓度组(53.6mg/ml)作用最为显著。
3.芳香运脾代表方-藿香正气可显著降低外周SP、VIP、ET水平(P<0.01,P<0.05,P<0.01),维持CGRP含量(P>0.05)。
4.芳香运脾代表药-藿香可显著降低外周SP、VIP及ET含量(P<0.01),藿香水提液、挥发油作用靶点不同。
5.芳香运脾代表方-藿香正气可提高脏体指数(P<0.05),有效降低IL-1B水平(P<0.05),明显提高IL-2含量(P<0.01),发挥免疫调节作用,但对于CORT含量无明显降低作用(P>0.05),。
结论
本研究以番泻叶水煎剂灌胃联合肢体束缚应激法,成功改良并复制了腹泻型肠易激综合征大鼠模型。芳香运脾法代表方-藿香正气通过调节外周胃肠激素水平,促炎因子和抑炎因子平衡,降低内脏敏感性和改善免疫炎性不平衡状态,从而缓解D-IBS症状,发挥其对于D-IBS的治疗作用。芳香运脾法代表药-藿香是通过多成分、多环节、多靶点的综合作用发挥治疗D-IBS的药效,因此在藿香正气制剂过程中不该随意丢弃主药藿香的有效成分。芳香运脾法则及其代表方药调节应激引发神经-内分泌-免疫网络紊乱,是中医学芳香运脾法调畅中焦脾胃气机、恢复脾胃健运功效的科学内涵之一。该法临床治疗D-IBS切入点与从肝论治---痛泻要方不同,该法则以脾胃升降功能失调为主要病机,适用于以腹泻为主证而伴有腹部不适者。
Objective:
Irritable bowel syndrome (IBS) is a common disease with gastrointestinal disorder functions, the clinical syndromes include abdominal pain, diarrhea or constipation, and abnormal bowel evacuation habit. It is without changes of structure and biochemistry. The incidence of IBS is very high, but its pathological mechanism is not completely illuminated. At present, the visceral hypersensitivity characterized by changed dynamic and abnormal sense is one of the important pathogenesis. The disharmony of neuroendocrine-immunity network secretion is advanced cognition.The gastrointestinal peptides and cytokines play important roles in the mechanism as middle transmitters. The common treatment is limited to symptomatic, there is no method to root it out now, while Chinese medicine have satisfying curative effect. So there are broad foregrounds of application of traditional Chinese medicine.
D-IBS belongs to the category of "diarrhea"、"abdominal pain" in traditional Chinese medicine. Its main mechanism is dysfunction of spleen and stomach, which leads to intestinal secretion of other features missing, liquid water can not infiltrate into the bladder,instead into colon, induce diarrea. Fragrant drugs can regulate the function of spleen and stomach, which has the features of elimination and benefit. Huoxiangzhegnqi is representative of fragrant drugs, which can regulate the activities of qi, eliminate the wetness-evil, invigorate the spleen and the stomach. It has good clinical effect on stopping diarrhea. But there is rare reports of research based on D-IBS. The purpose of our study is to explore the cure effect of Huoxiangzhengqi on D-IBS. By D-IBS rats model, we observe the opsonification of HXZQ on gut hormone and cytokine, in order to elucidate the adjusting visceral hypersensitivity and immunological function. We observe the effect of different ingredients in Agastache rugosa on some gut hormones, to discuss the diverse targets on D-IBS. All of our study will provide the scientific and reliable evidence for clinical application.
Methods:
1. D-IBS rats model is established by the combination of tied and intragastric administration Folium Cassiae.
2. Groups with different concentrations of HXZQ were established. Through testing the changes of the general status such as the body weight, the diarrhea condition, tail flick assay, saccule extension in rectum and colon, we try to explain the effect of HXZQ in adjusting the visceral hypersensitivity preliminarily and determine the best dose.
3. The level of SP、VIP、CGRP、ET and CORT were detected by radioimmunoassay and ELISA to show the adjusting effect of HXZQ on gut hormones.
4. In order to explore the effect of different ingredients in Agastache rugosa, we detected the level of SP、VIP and ET.
5. To discuss the adjusting effect of HXZQ on immunological function, we observed the atrophy degree of the spleen and thoracic gland, detected IL-1βand IL-2.
Results:
1. D-IBS rats showed obvious diarrhea, weight loss and immunological organs atrophied. There was no obvious injury by light microscope.
2. HXZQ may obviously degrade the diarrhea rate (P<0.05), inhibit the weight loss (P<0.01),and improve the abnormal visceral hypersensitivity(P<0.05).The medium dose was the best.
3. The medium dose of HXZQ can contribute to adjust the gut hormones, cut down the level of SP、VIP、ET, and keep the expression of CGRP(P>0.05).
4. Agastache rugosa also can adjust gut hormones(P<0.05). And different indigents have different effect targets.
5. The medium dose of HXZQ can improve the lower immunological conditions, degrade the expression of IL-1β(P<0.05) and elevate the level of IL-2 (P<0.01),except CORT(P>0.05).
Conclusions:
The model rats can induce the abnormal visceral hypersensitivity and immunological functions under stress. HXZQ, the representative of fragrant drugs, can adjust the expression of gut hormones and cytokines, improve the neuroendocrine-immunity network secretion to educe the therapeutical effect on D-IBS. Different indigents in Agastache rugosa have different effect targets, so in the procedure of making durgs we should not discard any indigent. Yunpi aromatic herbs and their representatives regulating stress-induced nerve-endocrine-immune network disorder, is one of the scientific content of regulating Qi in stomach and spleen, resuming their normal functions. Clinical treatment is different from the Liver pain Diarrhea, diarrhea accompanied by abdominal discomfort were its main syndromes.
引文
[1]李延青,杨云生,陈建.肠易激综合征[M],中国医药科技出版社,2005:48-49
[2]Gunter WD,Shepard JD,Foreman RD,et al.Evidence for visceral hypersensitivity in high-anxiety rats[J].Physiol Behav,2000,69(3):379-382.
[3]Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome[J].Gastroenterology,2002,122 (7):1778-1783.
[4]陈晓敏,张燕华,毛峻岭.肠易激综合征患者结肠黏膜P物质、血管活性肠肽和肥大细胞的变化[J].胃肠病学,2008,13(4)：228-230
[5]Park JH, Rhee PL, Kim HS, et al. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome[J].Gastroenterol Hepatol,2006,21 (1 Pt 1):71-78.
[6]Barbara G, Wang B, Stanghellini V, et al. Mast celldependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome[J]. Gastroenterology, 2007,132 (1):26-37.
[7]徐海珍,谢建群,等.腹泻型肠易激综合征大鼠结肠粘膜炎性细胞因子的表达及温中健脾方对其影响的研究[J].上海中医药杂志.2007,41(6):69-72
[8]李冬华,李春淼,李伍善,等.痛泻要方对肠易激综合征模型大鼠血管活性肠肽的影响[J].2007,18(9):2098-2099
[9]Williams CL, Villar RG, Peterson JM, et al. Stress-induced changes in intestinal transit in the rats-A model for irritable bowel syndrome[J]. Gastroenterology,1988, 94:611-621
[10]李延青,郭玉婷.肠易激综合征的动物模型研究[J].胃肠病学和肝病学杂志,2004,13(4):435-439
[11]Collions SM, MeHugh K, Jacobson K, et al.Previous inflammation alters the response of the rat colon to stress[J].Gastroenterology.1996, Dec,111 (6):1509-1515
[12]Scott RB, Tan DT, Miampamba M, et al.Anaphylaxis-induced alterations in intestinal motility:role of extrinsic neural pathways[J]. Am-J-Physiol,1998,275 (4Pt 1):G812-821
[13]徐叔云.药理实验方法学[M].北京：人民卫生出版社,2001：1340
[14]Ness TJ, Gebbat GF. Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudaffective reflexes in the rat[J]. Brain Res,1988(4),450:153-169
[15]AL-Chaer ED, Kawasaki M, Pasricha PJ, et al. A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development[J]. Gastroenterology,2000,119 (5):1276-1285
[16]谭涛,徐珊.肠易激综合征的各种动物模型及模型制作的完善思路[J].甘肃中医,2007,20(6)：16-19
[17]苗明三,朱飞鹏.常用医药研究动物模型[M].北京：人民卫生出版社,2007:359-360
[18]Santos J,Perdue MH. Stress and neuroimmune regulation of gut mucosal function. Gut,2000,47 (Suppl 4):iv49-iv51
[19]Tally NJ, Howell S, Poulton R. The irritable bowel syndrome and psychiatric disorders in the community:Is there a link? [J]. Am J Gastroenterol,2001,96 (4): 1072-1079
[20]Lule GN, Amayo EO.Irritable bowel syndrome in Kenyans [J].East Afr Med J,2002,79(7):360-363
[21]Drossman DA. Do Psychosocial factors define symptom severity and patient status in irritable bowel syndrome? [J].Am J Med,1999,107(5A):41S-50S.
[22]陈玉龙,王志铭,李幼辉,等.消化系统心身疾病的研究与临床[M].郑州大学出版社,2007,1.
[23]李红缨,周曾芬.肠易激综合征与精神心理因素[J].学院学报.2004,(3)：90-93
[24]Santos J,Perdue MH. Stress and neuroimmune regulation of gut mucosal function[J]. Gut,2000,47 (Suppl 4):iv49-iv51
[25]Mazzon E, Stumiolo GC, Puzzolo D, et al. Effect of stress on the Para cellular barrier in the rat ileum[J].Gut,2002,51:507-513
[26]沈映君,李仪奎.中药药理学[M].上海科学技术出版社,2003:73
[27]刘新光.肠易激综合征发病机制的研究现状[J].中华消化杂志,2001,21(7):391-392
[28]Lu GW, Li QJ,Meng Z, et al. Can we be aware of both visceral and somatic sensations via a single neuronal pathway? [J].Chin Sci Bull,2003,47:1940-1945.
[29]袁耀宗,刘雁冰,陶然君,等.肥大细胞在应激所致大鼠直肠高敏感性中的作用[J].中华消化杂志,2003,23(12)：727-730
[30]柳锋霖,孙燕,孙圣斌,等.急性束缚应激对大鼠结肠敏感性的影响[J].胃肠病学,2006,11(2)：99-102
[31]Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology,2006,130(5):1377-1390.
[32]谢肄聪,唐方.藿香正气软胶囊对肠屏障功能保护作用的机理研究[J]. 中国中药杂志,2004,29(5)：456-458
[33]Fang TANG, Hiroshi NODA, Masao YOSHIMURA, et al. The effects of water extract of Pogostemi Herba on intestinal mucosa of mice with Zinc abnormality [J].Journal of Traditional Medicines,1995,12:29-37
[34]谢肄聪,唐方.霍香正气软胶囊对肠屏障功能保护作用的实验研究[J].中草药,2003,31(3):252-254
[35]刘蓉.紫苏调节胃肠动力障碍大鼠肠运动功能的机理研究[D].天津医科大学,2007
[36]Gwee KA, Collins SM, Marshall JS, et al. Evidence of inflammatory pathogenesis in postinfectious irritable bowel syndrome[J].Gastroenterology,1998,114: A930
[37]王海云,石君杰.宁肠汤对肠易激综合征大鼠血清细胞因子作用的研究[J].现代中医药,2006,26(2)：37-39
[38]Ishikawa I, Kitamura H, Kimura K, et al. Brain interleukin-1 is inbllved in blood interleukin-6 response to immobilization stress in rats[J]. Jpn J Vet Res,2001, 49(1):19-25.
[39]Toumi F,Neunlist M,Cassagnau E, et al. Human submucosal neurones regulate intestinal epithelial cell proliferation:evidence from a novel co-culture mode[J]. Neurogast roenterol Motil,2003;15(3):239-242
[40]Kirkup AJ,Brunsden AM,Grundy D. Receptors and transmission in the brain-gut axis:potential for novel therapies. Ⅰ. Receptors on visceral afferents[J]. Am J Physiol Gast rointest Liver Physiol,2001;280(5):G7872-G794
[41]Mulak A,Bonaz B. Irritable bowel syndrome:a model of the brain-gut interactions[J]. Med Sci Monit,2004;10(4):RA55-62
[42]Konturek SJ, Pepera J,Zabielski K,et al. Brain-gut axis in pancreatic secretion and appetite control[J]. J Physiol Pharmacol,2003;54(3):293-317
[43]Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders[J]. Gastroenterology,2006 (130):1480-91.
[44]Quigley EM, Bytzer P, Jones R, Mearin F. Irritable bowel syndrome:The burden and unmet needs in Europe[J]. Dig Liver Dis,2006 (38):717-23.
[45]石志敏.调肝理脾通腑法治疗肠易激综合征便秘型的临床观察[D].成都中医药大学,2006.
[46]许明凯.乳腺增生病中医证候与心理应激相关性研究[D].北京中医药大学,2006
[47]赵荣莱.脾胃升降与功能性胃肠病[J].北京中医,2007,26(2):9-29
[48]Drossman DA. The functional gastrointestinal disorders and the Rome Ⅲ process. Gastroenterology,2006,130(5):1377-1390.
[49]江育仁.脾健不在补贵在运[J].中医杂志,1983,7(1)：6
[50]江育仁.脾健不在补贵在运[J].上海中医药杂志,2002,36(1)：4
[51]张骠,隆红艳.略论运脾学说的建立与发展及其对儿科临床的指导意义[J].江苏中医药,2008,40(11)：28-31
[52]翟宏丽,唐方.藿香正气软胶囊治疗动力障碍型功能性消化不良的临床疗效观察[J].中国中药杂志,2005,30(11)：865-866
[53]谢肄聪,唐方.藿香正气软胶囊对肠屏障功能保护作用的实验研究[J].中草药,2003,34(3)：252-254
[54]杨国汉,胡德耀,戴裕光,等.藿香正气液对大鼠胃动素的影响[J].第三军医大学学报,2006,28(2)：166-168
[55]袁晔蓉.藿香正气水对大鼠胃肠道影响的研究[J].实用医技杂志,2007,14(16)：2137-2138
[56]李瑛,卢健.试论芳香药的功用[J].江西中医药,2001,32(5)：50-51
[57]曹福凯,钱峻,金小晶,等.藿香正气散加减方治疗腹泻型肠易激综合征58例观察[J].安徽中医临床杂志,2003,15(5)：376-377
[58]张树卿.腹泻型肠易激综合征的中医临床研究进展[J].中医药临床杂志,2007,19(6)：635-637
[59]吕丹杨.藿香正气软胶囊治疗肠易激综合征58例临床观察[J].浙江中医杂志,2004,39(7)：308
[60]Smulevich AB, Rappoport SI, Syrkin AL, et al. Visceral neuroses:clinical approaches to the problem[J].Zh Nevrol Psikhiatr Im SS orsakova,2002,102(1):15-21
[61]Guthrie E, Creed F, Dawson D, Tomenson B. A controlled trial of psychological treatment for the irritable bowel syndrome. Gastroenterology,1991, 100:450-457.
[62]Williams M, Budavari A, Olden KW, Jones MP.Psychosocial assessment of functional gastrointestinal disorders in clinical practice[J]. J Clin Gastroenterol, 2005,39:847-857.
[63]Koloski NA, Talley NJ, Boyce PM. Does psychological distress modulate functional gastrointestinal symptoms and health care seeking? A prospective, community Cohort study [J]. Am J Gastorenteorl,2003,98:789-797.
[64]Bouin M, Plourde V, Boivin M, et al. Rectal distention testing in patients with irritable bowel syndrome:sensitivity, specificity, and predictive values of pain sensory thresholds[J]. Gastroenterology,2002,122(7):1771-1777.
[65]Delvaux M. Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome[J]. Gut,2002,51(Suppl 1):67-71.
[66]MONNIKFSH, TEBBE J J, HILDE BRANDT M,et al. Evidence for Stress-induced alterations in gastrointestinal motility and sensitivity [J]. Dig Dis, 2001,19(3):201-211.
[67]L. Ohman, M. Simren. New insights into the pathogenesis and pathophysiology of irritable bowel syndrome[J]. Digestive and Liver Disease,2007 (39):201-215
[68]May-EA, Collins SM. Evolving pathophysiologic models of fnnetional gastrointestinal disorders [J]. Gastroenterology,2002,122:2032-2048
[69]周吕,柯美云.神经胃肠病学与动力：基础与临床[M].科学出版社,2005,10.
[70]Suzuki R, Furuno T,M ckay DM, et al. D irect neurite-mast cell communication in v itro occurs v ia the neuropeptide substance P [J]. J Imm unol, 1999,163 (5):24102 2415.
[71]陈晓敏,张燕华,毛峻岭,等.肠易激综合征患者结肠黏膜P物质、血管活性肠肽和肥大细胞的变化[J].胃肠病学,2008,13(4)：228-230
[72]张茹.肠易激综合征血浆及乙状结肠黏膜中VIP及SS的含量[J].中国内镜杂志,2004,10(3):41-43
[73]桂先勇,潘国宗,柯美云,等.胃肠肽在应激所致结肠动力紊乱中的作用[J].中华医学杂志,1997,77(1)：31-34
[74]李合国,虞坚尔.整肠灵对脾胃虚寒星大鼠肠易激综合征的胃肠激素影响[J].河南医科大学学报,2002,21(3)：11-14
[75]李青,血管活性肠肽(VIP):抗炎与器官保护的实验研究进展[J].中国医疗前沿,2007,2(12)：66-67
[76]张玉杰,杨隽.血管活性肠肽的研究进展[J].畜牧与饲料科学,2006.4:39-41
[77]于新凯,左群,赛因贺西格,等.游泳运动对慢性心理应激大鼠延髓内皮素及受体的影响[J].上海体育学院学报,2008,32(1)：39-43
[78]朱永苹,林寿宁,黄适,等.水疗一号方对腹泻型肠易激综合征(湿热证)患的疗效及血浆NO和ET水平影响[J].广西中医学院学报,2007,10(3)：10-12
[79]金杭斌.神经-免疫-内分泌网络与肠易激综合征[J].国际消化病杂志,2006,26(1)：40-43
[80]孙怡宁,罗金燕,兰莉,等.替加色罗对结肠炎大鼠内脏敏感性的影响及其与结肠内P物质和降钙素基因相关肽表达的关系[J].西安交通大学学报(医学版),2007,28(5)：506-510
[81]冯国营,刘桂香.降钙素基因相关肽对胃肠作用的相关研究进展[J].滨州医学院学报,2008,31(4)：192-492
[82]Fyhrquist F, Saijonmaa 0, Mets rinne K, et al. Raised plasma endothelin-I concentration following cold pressor test [J].Biochem Biophys Res Commun, 1990,169(1):217-221
[83]Marchand JE, Sant GR, Kream RM.Increase expression of substance P receptor-encoding mRNA in bladder biopsies from patients with intestinal cystitis[J].Br J Urol,1998,81:224-228
[84]Pothoulakis C,Castagliuolo I,Leernan SE,et al.Substance P receptor expression in intestinal epithelium in clostridium difficile toxin A enteritis in rats[J].Am J Physiol,1998,275:G68-G75
[85]Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome[J]. Gastroenterology,2002,122:1778-1783
[86]Gwee KA, Collins SM, Marshall JS, et al. Evidence of inflammatory pathogenesis in postinfectious irritable bowel syndrome[J].Gastroenterology,1998,114: A930
[87]金杭斌.神经-免疫-内分泌网络与肠易激综合征[J].2006,26(1)：40-43
[88]张曼,张丽萍,刘海鹏.应激的神经-免疫-内分泌网络机制及中医药干预研究进展[J].神经解剖学杂志,2008,24(2):215-217
[89]谢兴振,迟晓丽,周文霞,等.应激动物模型研究进展[J].中国新药杂志,2008,17(16)：1375-1380
[90]张宴,肖健,耿晓峰,等.切断交感神经小鼠在情绪应激中免疫功能的改变[J].中国行为医学科学,2003,12(z):1-4.
[91]肖健,张晏,耿晓峰,等.应激引起不同年龄、性别和种类小鼠免疫器官退化的比较研究[J].北京大学学报,2000,36(5):725-731.
[92]鲁洪,宋德懋,冯娟,等.束缚应激上调小鼠脾脏淋巴细胞钾离子通道(Kv1.3)的表达[J].中国神经免疫学和神经病学杂志,2006,13(2)：113-116
[93]Kariagina A, Romanenko D, Ren SG, et al. Hypothalamic-pituitary cytokine network[J]. Endocrinology,2004,145(1):104-112.
[94]严灿,吴丽丽,徐志伟.应用心理应激理论和方法开展中医药实验研究的思路[J].广州中医药大学学报,2004,21(4):325-328.
[95]Blaekburn-Munro G. Hypothalamo-pituitary-adrenal axis dysfunction as a contributory factor to chronic pain and depression[J].. Curr Pain Headache Rep, 2004,8(2):116-124.
[96]袁芳,刘继文,连玉龙.应激对大鼠免疫功能的影响[J].中国职业医学,2005,32(6)：17-19
[97]Posserud I, Agerforz P, Ekman R, et al. Altered visceral perceptual and neuroendocrine response in patients with irritable bowel syndrome during mental stress[J]. Gut,2004,53:1102-1108.
[98]Greenwood-Van-Meerveld B, Johnson A C, Cochrane S, et al. Corticotropin-releasing factor 1 receptor-mediated mechanisms inhibit colonic hypersensitivity in rats[J]. Neurogastroenterol Motil,2005,17:415-422.
[99]张莉,哈木拉提·吾甫尔.细胞因子在神经-免疫-内分泌网络中的调节机制[J].免疫学杂志,2006,22(3):S128-134
[100]林文娟,王东林,潘玉芹.抑郁症的心理神经免疫学研究：细胞因子的作用[J].心理科学进展,2008,16(3)：404-410
[101]施桂兰,库宝善,姚海燕.解郁丸对慢性应激大鼠HPA轴和免疫系统的影响[J].中国中药杂志,2007,32(15):1551-1554
[102]宋继中,王巧民,吴正祥,等.细胞因子与IBS病人心理状况关系的初探[J].临床消化病杂志,2006,18(4):210-211
[103]罗慈伟,卓蕴雄,欧阳可鉴.脑外伤SIRS患者外周血中IL-2,IL-6的临床观察[J].中国临床神经外科杂志,2006,11(1)：34-35
[104]童瑶,邹军,刘平,等.四种中药复方对急性心理应激大鼠IL-1β和IL-2的影响[J].上海中医药大学学报,2005,19(2):32-34
[105]陈浩,柯美云.肠易激综合征与炎症关系的研究现状[J].国际消化病杂志,2007,27(3),172-177
[106]刘晗,高普均,宋然.炎症介质与肠易激综合征[J].中华中西医学杂志,2007,5(9)：8-9.
[107]袁旭江,朱盛山,李苑新,等.广藿香配方颗粒及其药材质量关系研究[J].时珍国医国药,2006,17(9)：1618-1619
[108]赵书策,贾强,廖富林.广藿香提取物的抗炎、镇痛药理研究[J].中成药,2007,29(2)：285-287
[109]陈小夏,何冰,李显奇,等.广藿香三种提取物对肠道功能作用的比较[J].中药药理与临床,1998,14(2)：31-33
[110]何冰,陈小夏,罗集鹏.广藿香去油部分的5种不同极性提取物对胃肠道的影 响[J].中药材,2001,24(6)：422-424
[111]张建英,楚更五,聂坚,等.痛泻要方治疗功能性脾虚腹泻的实验研究[J].中国中西医结合消化杂志,2008,16(3)：148-150
[112]陈文伟.石菖蒲、赤芍醇提取物对实验性抑郁及血管活性肠肽和P物质的影响[J].华西医学,2006,21(2)：321-322
[1]Olks D. The interface of psychiatry and irritable bowel syndrome[J]. Curr Psychiatry Rep,2004,6(3):210-215.
[2]Solmaz M, Kavuk I, Sayar K. PsychOlOgical factors in the irritable bowel syndrome[J].Eur J Med Res,2003,8(12):549-556.
[3]田云龙.肠易激综合征的病因及发病机制探讨[J].中国医学文摘·内科学,2005,26(5)：634-636.
[4]Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome:postal survey of patients [J]. BMJ,1997,314:779-782.
[5]李延青,郭玉婷.肠易激综合征的动物模型研究[J].胃肠病学和肝病学杂志,2004,13(4)：435-439.
[6]Spiller RC, Jenkins D, Thomley yp, et al, Increased rectal mucosal enteroendoerine cells. Tlymphocytes. and increased gut permeability following acute campylobaeter enteritis and is postdysenteric irritable bo we 1 syndrome [J]. Gut, 2000,47(6):804-811.
[7]胡品津,王伟岸,许岸高,等.广东省社区人群肠易激综合征的流行病学研究[J].中华医学杂志,2004,84(4)：278-281.
[8]王巧.肠易激综合征动力异常及其机制[J].医师进修杂志(内科版),2004,27(6)：54-55.
[9]李利生,曲瑞瑶,等.冷束缚应激大鼠十二指肠电—机械活动变化[J].首都医科大报.2002,23(4):300-302.
[10]VASSALLO M J, CAMILLERI M, PHILLIPS S F, et al. Colonic tone and motility in patients with irritable bowel syndrome [J]. Mayo Clin,1992,67:725-731.
[11]杜芳腾,刘晶美,罗文.肠易激综合征直肠肛管测压研究[J].江西医药杂志,1999,34(1)：7-8.
[12]Costa M, Brookes SH, Zagorodnyuk V. How many kinds of visceral afferents? [J]Gut,2004,53(Suppl 2):ⅱ1-ⅱ4.
[13]董文珠,邹多武,李兆申,等.肠易激综合征患者内脏高敏感性的机制研究[J].中华消化杂志.2004,24(1)：18-22.
[14]Simren M, Abrahamsson H. Bjornsson ES. An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome[J]. Gut.2001,48:20-27.
[15]Sinhamahapatra P. Saha SP, Chowdhury A, et al. Visceral afferent hyperscnsitivy in irritable bowel syndrome-evaluation by cerebral evoked potential after rectal stimulation[J]. Am J Gastroenterol.2001,96:2150-2157.
[16]沈骏.脑肠肽在肠易激综合征中的作用[J].国外医学·消化系疾病分册.2004,24(3)：169-171.
[17]曾芝君.中枢神经系统异常在肠易激综合征内脏高敏感性形成中的作用[J].胃肠病学.2006,11(3):187-189.
[18]姜敏,凌立平,傅宝玉.肠易激综合征患者结肠5-HT的分布特点[J].世界华人消化杂志.2005,13(4):541-543.
[19]熊慧珍,祝金泉.肠嗜铬细胞及其分泌的5-羟色胺在肠易激综合征中的作用[J].江西医药.2006,41(6):423-426.
[20]丁健华,傅传刚,赵荣华.五羟色胺在胃肠道功能性疾病中的研究现状[J].世界华人消化杂志.2005,13(20):2405-2408
[21]李运红,朱晓蕾,徐肇敏.腹泻型肠易激综合征患者结肠黏膜5-羟色胺和5-羟色胺3受体的研究[J].胃肠病学.2006,11(8):477-480.
[22]Nishiyama H, Mizuta Y, Isomoto H, Takeshima F, Omagari K, Miyahara Y, Murata I, Kohno S. Chronic visceral hypersensitivity renders defecation mole susceptible to stress via a serotonergic pathway in rats[J]. Dig Dis Sci,2004,49: 763-769.
[23]Houghton LA, Foster JM, Whorwell PJ. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers[J]. Aliment Pharmacol Ther,2000,14:775-782.
[24]Ho A, Lievore A, Patierno S,at al. AddedNeurochemically distinct classes of myenteric neurons express the mu-opioid receptor in the guinea pig ileum[J]. Comp Neurol,2003; 458: 404-411.
[25]Itoh A, Tsujikawa T, Fujiyama Y, at al. Enhancement of aquaporin-3 by vasoactive intestinal polypeptide in a human colonic epithelial cell line[J]. Gastroenterol Hepatol,2003; 18:203-221.
[26]胡旭光,杨超燕,等.痛泻要方对两种腹泻型肠易激综合征模型大鼠的止痛止泻作用研究[J].中华临床医学研究杂志.2007,13(9):1125-1126.
[27]续海卿.逍遥散加减治疗肠易激综合征[J].四川中医.2003,21(7)：48.
[28]李富增.加味麻仁润肠丸治疗肠易激综合征便秘型40例.实用中医内科杂志[J].2004,18(4)：353-354.
[29]李红缨,周曾芬.肠易激综合征与精神心理因素[J].学院学报.2004,(3):90-93
[30]Santos J,Perdue MH. Stress and neuroimmune regulation of gut mucosal function[J]. Gut,2000,47 (Suppl 4):iv49-iv51
[31]宋继中.肠易激综合征患者血清、结肠粘膜炎症反应及其粘膜免疫变化的研究[J].安徽医科大学,2005
[32]孙怡宁,罗金燕,兰莉,等.替加色罗对结肠炎大鼠内脏敏感性的影响及其与结肠内P物质和降钙素基因相关肽表达的关系[J].西安交通大学学报(医学版),2007,28(5)：506-510
[33]冯国营,刘桂香.降钙素基因相关肽对胃肠作用的相关研究进展[J].滨州医学院学报,2008,31(4)：192-492
[2]Gunter WD,Shepard JD,Foreman RD,et al.Evidence for visceral hypersensitivity in high-anxiety rats[J].Physiol Behav,2000,69(3):379-382.
[3]Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome[J].Gastroenterology,2002,122 (7):1778-1783.
[4]陈晓敏,张燕华,毛峻岭.肠易激综合征患者结肠黏膜P物质、血管活性肠肽和肥大细胞的变化[J].胃肠病学,2008,13(4)：228-230
[5]Park JH, Rhee PL, Kim HS, et al. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome[J].Gastroenterol Hepatol,2006,21 (1 Pt 1):71-78.
[6]Barbara G, Wang B, Stanghellini V, et al. Mast celldependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome[J]. Gastroenterology, 2007,132 (1):26-37.
[7]徐海珍,谢建群,等.腹泻型肠易激综合征大鼠结肠粘膜炎性细胞因子的表达及温中健脾方对其影响的研究[J].上海中医药杂志.2007,41(6):69-72
[8]李冬华,李春淼,李伍善,等.痛泻要方对肠易激综合征模型大鼠血管活性肠肽的影响[J].2007,18(9):2098-2099
[9]Williams CL, Villar RG, Peterson JM, et al. Stress-induced changes in intestinal transit in the rats-A model for irritable bowel syndrome[J]. Gastroenterology,1988, 94:611-621
[10]李延青,郭玉婷.肠易激综合征的动物模型研究[J].胃肠病学和肝病学杂志,2004,13(4):435-439
[11]Collions SM, MeHugh K, Jacobson K, et al.Previous inflammation alters the response of the rat colon to stress[J].Gastroenterology.1996, Dec,111 (6):1509-1515
[12]Scott RB, Tan DT, Miampamba M, et al.Anaphylaxis-induced alterations in intestinal motility:role of extrinsic neural pathways[J]. Am-J-Physiol,1998,275 (4Pt 1):G812-821
[13]徐叔云.药理实验方法学[M].北京：人民卫生出版社,2001：1340
[14]Ness TJ, Gebbat GF. Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudaffective reflexes in the rat[J]. Brain Res,1988(4),450:153-169
[15]AL-Chaer ED, Kawasaki M, Pasricha PJ, et al. A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development[J]. Gastroenterology,2000,119 (5):1276-1285
[16]谭涛,徐珊.肠易激综合征的各种动物模型及模型制作的完善思路[J].甘肃中医,2007,20(6)：16-19
[17]苗明三,朱飞鹏.常用医药研究动物模型[M].北京：人民卫生出版社,2007:359-360
[18]Santos J,Perdue MH. Stress and neuroimmune regulation of gut mucosal function. Gut,2000,47 (Suppl 4):iv49-iv51
[19]Tally NJ, Howell S, Poulton R. The irritable bowel syndrome and psychiatric disorders in the community:Is there a link? [J]. Am J Gastroenterol,2001,96 (4): 1072-1079
[20]Lule GN, Amayo EO.Irritable bowel syndrome in Kenyans [J].East Afr Med J,2002,79(7):360-363
[21]Drossman DA. Do Psychosocial factors define symptom severity and patient status in irritable bowel syndrome? [J].Am J Med,1999,107(5A):41S-50S.
[22]陈玉龙,王志铭,李幼辉,等.消化系统心身疾病的研究与临床[M].郑州大学出版社,2007,1.
[23]李红缨,周曾芬.肠易激综合征与精神心理因素[J].学院学报.2004,(3)：90-93
[24]Santos J,Perdue MH. Stress and neuroimmune regulation of gut mucosal function[J]. Gut,2000,47 (Suppl 4):iv49-iv51
[25]Mazzon E, Stumiolo GC, Puzzolo D, et al. Effect of stress on the Para cellular barrier in the rat ileum[J].Gut,2002,51:507-513
[26]沈映君,李仪奎.中药药理学[M].上海科学技术出版社,2003:73
[27]刘新光.肠易激综合征发病机制的研究现状[J].中华消化杂志,2001,21(7):391-392
[28]Lu GW, Li QJ,Meng Z, et al. Can we be aware of both visceral and somatic sensations via a single neuronal pathway? [J].Chin Sci Bull,2003,47:1940-1945.
[29]袁耀宗,刘雁冰,陶然君,等.肥大细胞在应激所致大鼠直肠高敏感性中的作用[J].中华消化杂志,2003,23(12)：727-730
[30]柳锋霖,孙燕,孙圣斌,等.急性束缚应激对大鼠结肠敏感性的影响[J].胃肠病学,2006,11(2)：99-102
[31]Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology,2006,130(5):1377-1390.
[32]谢肄聪,唐方.藿香正气软胶囊对肠屏障功能保护作用的机理研究[J]. 中国中药杂志,2004,29(5)：456-458
[33]Fang TANG, Hiroshi NODA, Masao YOSHIMURA, et al. The effects of water extract of Pogostemi Herba on intestinal mucosa of mice with Zinc abnormality [J].Journal of Traditional Medicines,1995,12:29-37
[34]谢肄聪,唐方.霍香正气软胶囊对肠屏障功能保护作用的实验研究[J].中草药,2003,31(3):252-254
[35]刘蓉.紫苏调节胃肠动力障碍大鼠肠运动功能的机理研究[D].天津医科大学,2007
[36]Gwee KA, Collins SM, Marshall JS, et al. Evidence of inflammatory pathogenesis in postinfectious irritable bowel syndrome[J].Gastroenterology,1998,114: A930
[37]王海云,石君杰.宁肠汤对肠易激综合征大鼠血清细胞因子作用的研究[J].现代中医药,2006,26(2)：37-39
[38]Ishikawa I, Kitamura H, Kimura K, et al. Brain interleukin-1 is inbllved in blood interleukin-6 response to immobilization stress in rats[J]. Jpn J Vet Res,2001, 49(1):19-25.
[39]Toumi F,Neunlist M,Cassagnau E, et al. Human submucosal neurones regulate intestinal epithelial cell proliferation:evidence from a novel co-culture mode[J]. Neurogast roenterol Motil,2003;15(3):239-242
[40]Kirkup AJ,Brunsden AM,Grundy D. Receptors and transmission in the brain-gut axis:potential for novel therapies. Ⅰ. Receptors on visceral afferents[J]. Am J Physiol Gast rointest Liver Physiol,2001;280(5):G7872-G794
[41]Mulak A,Bonaz B. Irritable bowel syndrome:a model of the brain-gut interactions[J]. Med Sci Monit,2004;10(4):RA55-62
[42]Konturek SJ, Pepera J,Zabielski K,et al. Brain-gut axis in pancreatic secretion and appetite control[J]. J Physiol Pharmacol,2003;54(3):293-317
[43]Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders[J]. Gastroenterology,2006 (130):1480-91.
[44]Quigley EM, Bytzer P, Jones R, Mearin F. Irritable bowel syndrome:The burden and unmet needs in Europe[J]. Dig Liver Dis,2006 (38):717-23.
[45]石志敏.调肝理脾通腑法治疗肠易激综合征便秘型的临床观察[D].成都中医药大学,2006.
[46]许明凯.乳腺增生病中医证候与心理应激相关性研究[D].北京中医药大学,2006
[47]赵荣莱.脾胃升降与功能性胃肠病[J].北京中医,2007,26(2):9-29
[48]Drossman DA. The functional gastrointestinal disorders and the Rome Ⅲ process. Gastroenterology,2006,130(5):1377-1390.
[49]江育仁.脾健不在补贵在运[J].中医杂志,1983,7(1)：6
[50]江育仁.脾健不在补贵在运[J].上海中医药杂志,2002,36(1)：4
[51]张骠,隆红艳.略论运脾学说的建立与发展及其对儿科临床的指导意义[J].江苏中医药,2008,40(11)：28-31
[52]翟宏丽,唐方.藿香正气软胶囊治疗动力障碍型功能性消化不良的临床疗效观察[J].中国中药杂志,2005,30(11)：865-866
[53]谢肄聪,唐方.藿香正气软胶囊对肠屏障功能保护作用的实验研究[J].中草药,2003,34(3)：252-254
[54]杨国汉,胡德耀,戴裕光,等.藿香正气液对大鼠胃动素的影响[J].第三军医大学学报,2006,28(2)：166-168
[55]袁晔蓉.藿香正气水对大鼠胃肠道影响的研究[J].实用医技杂志,2007,14(16)：2137-2138
[56]李瑛,卢健.试论芳香药的功用[J].江西中医药,2001,32(5)：50-51
[57]曹福凯,钱峻,金小晶,等.藿香正气散加减方治疗腹泻型肠易激综合征58例观察[J].安徽中医临床杂志,2003,15(5)：376-377
[58]张树卿.腹泻型肠易激综合征的中医临床研究进展[J].中医药临床杂志,2007,19(6)：635-637
[59]吕丹杨.藿香正气软胶囊治疗肠易激综合征58例临床观察[J].浙江中医杂志,2004,39(7)：308
[60]Smulevich AB, Rappoport SI, Syrkin AL, et al. Visceral neuroses:clinical approaches to the problem[J].Zh Nevrol Psikhiatr Im SS orsakova,2002,102(1):15-21
[61]Guthrie E, Creed F, Dawson D, Tomenson B. A controlled trial of psychological treatment for the irritable bowel syndrome. Gastroenterology,1991, 100:450-457.
[62]Williams M, Budavari A, Olden KW, Jones MP.Psychosocial assessment of functional gastrointestinal disorders in clinical practice[J]. J Clin Gastroenterol, 2005,39:847-857.
[63]Koloski NA, Talley NJ, Boyce PM. Does psychological distress modulate functional gastrointestinal symptoms and health care seeking? A prospective, community Cohort study [J]. Am J Gastorenteorl,2003,98:789-797.
[64]Bouin M, Plourde V, Boivin M, et al. Rectal distention testing in patients with irritable bowel syndrome:sensitivity, specificity, and predictive values of pain sensory thresholds[J]. Gastroenterology,2002,122(7):1771-1777.
[65]Delvaux M. Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome[J]. Gut,2002,51(Suppl 1):67-71.
[66]MONNIKFSH, TEBBE J J, HILDE BRANDT M,et al. Evidence for Stress-induced alterations in gastrointestinal motility and sensitivity [J]. Dig Dis, 2001,19(3):201-211.
[67]L. Ohman, M. Simren. New insights into the pathogenesis and pathophysiology of irritable bowel syndrome[J]. Digestive and Liver Disease,2007 (39):201-215
[68]May-EA, Collins SM. Evolving pathophysiologic models of fnnetional gastrointestinal disorders [J]. Gastroenterology,2002,122:2032-2048
[69]周吕,柯美云.神经胃肠病学与动力：基础与临床[M].科学出版社,2005,10.
[70]Suzuki R, Furuno T,M ckay DM, et al. D irect neurite-mast cell communication in v itro occurs v ia the neuropeptide substance P [J]. J Imm unol, 1999,163 (5):24102 2415.
[71]陈晓敏,张燕华,毛峻岭,等.肠易激综合征患者结肠黏膜P物质、血管活性肠肽和肥大细胞的变化[J].胃肠病学,2008,13(4)：228-230
[72]张茹.肠易激综合征血浆及乙状结肠黏膜中VIP及SS的含量[J].中国内镜杂志,2004,10(3):41-43
[73]桂先勇,潘国宗,柯美云,等.胃肠肽在应激所致结肠动力紊乱中的作用[J].中华医学杂志,1997,77(1)：31-34
[74]李合国,虞坚尔.整肠灵对脾胃虚寒星大鼠肠易激综合征的胃肠激素影响[J].河南医科大学学报,2002,21(3)：11-14
[75]李青,血管活性肠肽(VIP):抗炎与器官保护的实验研究进展[J].中国医疗前沿,2007,2(12)：66-67
[76]张玉杰,杨隽.血管活性肠肽的研究进展[J].畜牧与饲料科学,2006.4:39-41
[77]于新凯,左群,赛因贺西格,等.游泳运动对慢性心理应激大鼠延髓内皮素及受体的影响[J].上海体育学院学报,2008,32(1)：39-43
[78]朱永苹,林寿宁,黄适,等.水疗一号方对腹泻型肠易激综合征(湿热证)患的疗效及血浆NO和ET水平影响[J].广西中医学院学报,2007,10(3)：10-12
[79]金杭斌.神经-免疫-内分泌网络与肠易激综合征[J].国际消化病杂志,2006,26(1)：40-43
[80]孙怡宁,罗金燕,兰莉,等.替加色罗对结肠炎大鼠内脏敏感性的影响及其与结肠内P物质和降钙素基因相关肽表达的关系[J].西安交通大学学报(医学版),2007,28(5)：506-510
[81]冯国营,刘桂香.降钙素基因相关肽对胃肠作用的相关研究进展[J].滨州医学院学报,2008,31(4)：192-492
[82]Fyhrquist F, Saijonmaa 0, Mets rinne K, et al. Raised plasma endothelin-I concentration following cold pressor test [J].Biochem Biophys Res Commun, 1990,169(1):217-221
[83]Marchand JE, Sant GR, Kream RM.Increase expression of substance P receptor-encoding mRNA in bladder biopsies from patients with intestinal cystitis[J].Br J Urol,1998,81:224-228
[84]Pothoulakis C,Castagliuolo I,Leernan SE,et al.Substance P receptor expression in intestinal epithelium in clostridium difficile toxin A enteritis in rats[J].Am J Physiol,1998,275:G68-G75
[85]Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome[J]. Gastroenterology,2002,122:1778-1783
[86]Gwee KA, Collins SM, Marshall JS, et al. Evidence of inflammatory pathogenesis in postinfectious irritable bowel syndrome[J].Gastroenterology,1998,114: A930
[87]金杭斌.神经-免疫-内分泌网络与肠易激综合征[J].2006,26(1)：40-43
[88]张曼,张丽萍,刘海鹏.应激的神经-免疫-内分泌网络机制及中医药干预研究进展[J].神经解剖学杂志,2008,24(2):215-217
[89]谢兴振,迟晓丽,周文霞,等.应激动物模型研究进展[J].中国新药杂志,2008,17(16)：1375-1380
[90]张宴,肖健,耿晓峰,等.切断交感神经小鼠在情绪应激中免疫功能的改变[J].中国行为医学科学,2003,12(z):1-4.
[91]肖健,张晏,耿晓峰,等.应激引起不同年龄、性别和种类小鼠免疫器官退化的比较研究[J].北京大学学报,2000,36(5):725-731.
[92]鲁洪,宋德懋,冯娟,等.束缚应激上调小鼠脾脏淋巴细胞钾离子通道(Kv1.3)的表达[J].中国神经免疫学和神经病学杂志,2006,13(2)：113-116
[93]Kariagina A, Romanenko D, Ren SG, et al. Hypothalamic-pituitary cytokine network[J]. Endocrinology,2004,145(1):104-112.
[94]严灿,吴丽丽,徐志伟.应用心理应激理论和方法开展中医药实验研究的思路[J].广州中医药大学学报,2004,21(4):325-328.
[95]Blaekburn-Munro G. Hypothalamo-pituitary-adrenal axis dysfunction as a contributory factor to chronic pain and depression[J].. Curr Pain Headache Rep, 2004,8(2):116-124.
[96]袁芳,刘继文,连玉龙.应激对大鼠免疫功能的影响[J].中国职业医学,2005,32(6)：17-19
[97]Posserud I, Agerforz P, Ekman R, et al. Altered visceral perceptual and neuroendocrine response in patients with irritable bowel syndrome during mental stress[J]. Gut,2004,53:1102-1108.
[98]Greenwood-Van-Meerveld B, Johnson A C, Cochrane S, et al. Corticotropin-releasing factor 1 receptor-mediated mechanisms inhibit colonic hypersensitivity in rats[J]. Neurogastroenterol Motil,2005,17:415-422.
[99]张莉,哈木拉提·吾甫尔.细胞因子在神经-免疫-内分泌网络中的调节机制[J].免疫学杂志,2006,22(3):S128-134
[100]林文娟,王东林,潘玉芹.抑郁症的心理神经免疫学研究：细胞因子的作用[J].心理科学进展,2008,16(3)：404-410
[101]施桂兰,库宝善,姚海燕.解郁丸对慢性应激大鼠HPA轴和免疫系统的影响[J].中国中药杂志,2007,32(15):1551-1554
[102]宋继中,王巧民,吴正祥,等.细胞因子与IBS病人心理状况关系的初探[J].临床消化病杂志,2006,18(4):210-211
[103]罗慈伟,卓蕴雄,欧阳可鉴.脑外伤SIRS患者外周血中IL-2,IL-6的临床观察[J].中国临床神经外科杂志,2006,11(1)：34-35
[104]童瑶,邹军,刘平,等.四种中药复方对急性心理应激大鼠IL-1β和IL-2的影响[J].上海中医药大学学报,2005,19(2):32-34
[105]陈浩,柯美云.肠易激综合征与炎症关系的研究现状[J].国际消化病杂志,2007,27(3),172-177
[106]刘晗,高普均,宋然.炎症介质与肠易激综合征[J].中华中西医学杂志,2007,5(9)：8-9.
[107]袁旭江,朱盛山,李苑新,等.广藿香配方颗粒及其药材质量关系研究[J].时珍国医国药,2006,17(9)：1618-1619
[108]赵书策,贾强,廖富林.广藿香提取物的抗炎、镇痛药理研究[J].中成药,2007,29(2)：285-287
[109]陈小夏,何冰,李显奇,等.广藿香三种提取物对肠道功能作用的比较[J].中药药理与临床,1998,14(2)：31-33
[110]何冰,陈小夏,罗集鹏.广藿香去油部分的5种不同极性提取物对胃肠道的影 响[J].中药材,2001,24(6)：422-424
[111]张建英,楚更五,聂坚,等.痛泻要方治疗功能性脾虚腹泻的实验研究[J].中国中西医结合消化杂志,2008,16(3)：148-150
[112]陈文伟.石菖蒲、赤芍醇提取物对实验性抑郁及血管活性肠肽和P物质的影响[J].华西医学,2006,21(2)：321-322
[1]Olks D. The interface of psychiatry and irritable bowel syndrome[J]. Curr Psychiatry Rep,2004,6(3):210-215.
[2]Solmaz M, Kavuk I, Sayar K. PsychOlOgical factors in the irritable bowel syndrome[J].Eur J Med Res,2003,8(12):549-556.
[3]田云龙.肠易激综合征的病因及发病机制探讨[J].中国医学文摘·内科学,2005,26(5)：634-636.
[4]Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome:postal survey of patients [J]. BMJ,1997,314:779-782.
[5]李延青,郭玉婷.肠易激综合征的动物模型研究[J].胃肠病学和肝病学杂志,2004,13(4)：435-439.
[6]Spiller RC, Jenkins D, Thomley yp, et al, Increased rectal mucosal enteroendoerine cells. Tlymphocytes. and increased gut permeability following acute campylobaeter enteritis and is postdysenteric irritable bo we 1 syndrome [J]. Gut, 2000,47(6):804-811.
[7]胡品津,王伟岸,许岸高,等.广东省社区人群肠易激综合征的流行病学研究[J].中华医学杂志,2004,84(4)：278-281.
[8]王巧.肠易激综合征动力异常及其机制[J].医师进修杂志(内科版),2004,27(6)：54-55.
[9]李利生,曲瑞瑶,等.冷束缚应激大鼠十二指肠电—机械活动变化[J].首都医科大报.2002,23(4):300-302.
[10]VASSALLO M J, CAMILLERI M, PHILLIPS S F, et al. Colonic tone and motility in patients with irritable bowel syndrome [J]. Mayo Clin,1992,67:725-731.
[11]杜芳腾,刘晶美,罗文.肠易激综合征直肠肛管测压研究[J].江西医药杂志,1999,34(1)：7-8.
[12]Costa M, Brookes SH, Zagorodnyuk V. How many kinds of visceral afferents? [J]Gut,2004,53(Suppl 2):ⅱ1-ⅱ4.
[13]董文珠,邹多武,李兆申,等.肠易激综合征患者内脏高敏感性的机制研究[J].中华消化杂志.2004,24(1)：18-22.
[14]Simren M, Abrahamsson H. Bjornsson ES. An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome[J]. Gut.2001,48:20-27.
[15]Sinhamahapatra P. Saha SP, Chowdhury A, et al. Visceral afferent hyperscnsitivy in irritable bowel syndrome-evaluation by cerebral evoked potential after rectal stimulation[J]. Am J Gastroenterol.2001,96:2150-2157.
[16]沈骏.脑肠肽在肠易激综合征中的作用[J].国外医学·消化系疾病分册.2004,24(3)：169-171.
[17]曾芝君.中枢神经系统异常在肠易激综合征内脏高敏感性形成中的作用[J].胃肠病学.2006,11(3):187-189.
[18]姜敏,凌立平,傅宝玉.肠易激综合征患者结肠5-HT的分布特点[J].世界华人消化杂志.2005,13(4):541-543.
[19]熊慧珍,祝金泉.肠嗜铬细胞及其分泌的5-羟色胺在肠易激综合征中的作用[J].江西医药.2006,41(6):423-426.
[20]丁健华,傅传刚,赵荣华.五羟色胺在胃肠道功能性疾病中的研究现状[J].世界华人消化杂志.2005,13(20):2405-2408
[21]李运红,朱晓蕾,徐肇敏.腹泻型肠易激综合征患者结肠黏膜5-羟色胺和5-羟色胺3受体的研究[J].胃肠病学.2006,11(8):477-480.
[22]Nishiyama H, Mizuta Y, Isomoto H, Takeshima F, Omagari K, Miyahara Y, Murata I, Kohno S. Chronic visceral hypersensitivity renders defecation mole susceptible to stress via a serotonergic pathway in rats[J]. Dig Dis Sci,2004,49: 763-769.
[23]Houghton LA, Foster JM, Whorwell PJ. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers[J]. Aliment Pharmacol Ther,2000,14:775-782.
[24]Ho A, Lievore A, Patierno S,at al. AddedNeurochemically distinct classes of myenteric neurons express the mu-opioid receptor in the guinea pig ileum[J]. Comp Neurol,2003; 458: 404-411.
[25]Itoh A, Tsujikawa T, Fujiyama Y, at al. Enhancement of aquaporin-3 by vasoactive intestinal polypeptide in a human colonic epithelial cell line[J]. Gastroenterol Hepatol,2003; 18:203-221.
[26]胡旭光,杨超燕,等.痛泻要方对两种腹泻型肠易激综合征模型大鼠的止痛止泻作用研究[J].中华临床医学研究杂志.2007,13(9):1125-1126.
[27]续海卿.逍遥散加减治疗肠易激综合征[J].四川中医.2003,21(7)：48.
[28]李富增.加味麻仁润肠丸治疗肠易激综合征便秘型40例.实用中医内科杂志[J].2004,18(4)：353-354.
[29]李红缨,周曾芬.肠易激综合征与精神心理因素[J].学院学报.2004,(3):90-93
[30]Santos J,Perdue MH. Stress and neuroimmune regulation of gut mucosal function[J]. Gut,2000,47 (Suppl 4):iv49-iv51
[31]宋继中.肠易激综合征患者血清、结肠粘膜炎症反应及其粘膜免疫变化的研究[J].安徽医科大学,2005
[32]孙怡宁,罗金燕,兰莉,等.替加色罗对结肠炎大鼠内脏敏感性的影响及其与结肠内P物质和降钙素基因相关肽表达的关系[J].西安交通大学学报(医学版),2007,28(5)：506-510
[33]冯国营,刘桂香.降钙素基因相关肽对胃肠作用的相关研究进展[J].滨州医学院学报,2008,31(4)：192-492